Navigation Links
Among Newly Diagnosed Type 2 Diabetes Patients, DPP-IV Inhibitors are the Leading Oral Therapies After Standard Metformin and Sulfonylurea
Date:10/2/2013

BURLINGTON, Mass., Oct. 2, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through analysis of U.S. longitudinal patient-level claims data, dipeptidyl peptidase (DPP-IV) inhibitors claim the largest share among branded oral therapies of newly diagnosed type 2 diabetes patients across all three lines of therapy. DPP-IV inhibitors include Merck's Januvia, Bristol-Myers Squibb/AstraZeneca's Onglyza and Boehringer Ingelheim's Tradjenta. According to Treatment Algorithms in Type 2 Diabetes, metformin and sulfonylureas continue to dominate first-line therapy use, while long-acting insulins are also more heavily used as a first-line therapy than the DPP-IV inhibitors, despite ADA/EASD guidelines recommending oral antidiabetic therapy prior to insulin administration.

The report also examines recently treated type 2 diabetes patients. This group represents patients treated in the first quarter of 2013 and reviews retrospective analysis of the preceding two years of therapy. The year-over-year trend analysis found that among recently treated patients use of rapid- and long-acting insulins continue to gain patient share, while DPP-IV inhibitors and GLP-1 receptor agonists' patient share also steadily grow, which is likely to be at the expense of the PPAR-gamma agonists.

"The increased use of long-acting insulins such as Sanofi's Lantus as a first line treatment may indicate that physicians are implementing more aggressive initial therapy than suggested in the treatment guidelines in an attempt to improve glycemic control," said Decision Resources Analyst Eamonn O'Connor, Ph.D. "However, the increased use of rapid-acting insulins would indicate that current long-acting insulins are failing to provide complete 24-hour glycemic control."

The analysis is part of Decision Resources' Treatment Algorithms Insight series, which through examination of U.S. longitudinal patient-level claims data, provides exceptional insight into physicians' prescribing trends, from diagnosis through multiple courses of treatment, for a specific disease. Quarterly data analysis reveals progression rates of patients through each line of therapy, the share each brand commands by line of therapy and add-versus-switch patterns to key brands.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or
registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Dr. Prem Reddy Named Among Most Influential Physician Executives in Nation
2. Brain Research Foundation Announces Grant To Study Concussive Events Among Grade School Children
3. Imaging Healthcare Specialists Among the First in the Nation to Offer Imaging Diagnosis for Alzheimers Disease
4. Advanced Radiology Among the First in the U.S. to Offer New Alzheimers Disease Tracer
5. Social Norms, Life Changes and Increasing Pressures Contribute to Substance Abuse Among Adult Women
6. Frost & Sullivan: Miniaturization of Medical Devices Reduces Mortality Rates among Cardiac Dysrhythmia Patients
7. Takedas Deerfield Campus Ranked Among Chicagos Top 100 Workplaces in 2012
8. CBIS Releases Corporate Operational Guidance for 2013 as the Company Reorganizes to better meet the Growing Global Crisis Associated with Anti-Retroviral Drug Resistance among People with AIDS, as well as the Increasing Need for Patient Friendly Ski
9. Forbes Ranks SynCardia Among "Americas Most Promising Companies" for Second Straight Year
10. GNC NutriWater, COTYs Beyonce Pulse NYC, Swansons Super DPA Fish Oil, Among First SupplySide Insights Awards Finalists
11. Poorest U.S. States Rank Among Most Wasteful in Unnecessary Medication-Related Costs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
(Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data derived ... Assessment of major trends with potential impact on the market ... of market segmentation which comprises of sub markets, regional and ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB ... Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards ... in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With ...
(Date:6/24/2016)... , ... June 24, 2016 , ... National recruitment firm ... life sciences executive with extensive sequencing and genomics experience, as Vice President of North ... Ms. Hill will be responsible for leading the sales team in the commercialization of ...
Breaking Medicine News(10 mins):